Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? A multicenter, randomized, controlled, open-label trial was written by Eklof, Josefin;Alispahic, Imane Achir;Sivapalan, Pradeesh;Wilcke, Torgny;Seersholm, Niels;Armbruster, Karin;Kjaergaard, Jakob Lyngby;Saeed, Mohamad Isam;Nielsen, Thyge Lynghoej;Browatzki, Andrea;Overgaard, Rikke Holmen;Fenlev, Camilla Sund;Harboe, Zitta Barella;Andreassen, Helle Frost;Lapperre, Therese Sophie;Pedersen, Lars;Johnsen, Stine;Ulrik, Charlotte Suppli;Janner, Julie;Moberg, Mia;Heidemann, Maria;Weinreich, Ulla Moeller;Vijdea, Roxana;Linde, Hans;Titlestad, Ingrid;Johansson, Sofie Lock;Rosenvinge, Flemming Schoenning;Oestergaard, Christian;Ghathian, Khaled Saoud Ali;Gundersen, Lise;Christensen, Christina Wellendorph;Bangsborg, Jette;Jensen, Torben Tranborg;Soerensen, Vibeke Muff;Ellingsgaard, Thilde;Datcu, Raluca;Coia, John Eugenio;Bodtger, Uffe;Jensen, Jens Ulrik Staehr. And the article was included in Trials in 2022.Synthetic Route of C17H18FN3O3 This article mentions the following:
Abstract: Background: Pseudomonas aeruginosa infection is seen in chronic pulmonary disease and is associated with exacerbations and poor long-term prognosis. However, evidence-based guidelines for the management and treatment of P. aeruginosa infection in chronic, non-cystic fibrosis (CF) pulmonary disease are lacking. The aim of this study is to investigate whether targeted antibiotic treatment against P. aeruginosa can reduce exacerbations and mortality in patients with chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis, and asthma. Methods: This study is an ongoing multicenter, randomized, controlled, open-label trial. A total of 150 patients with COPD, non-CF bronchiectasis or asthma, and P. aeruginosa-pos. lower respiratory tract samples will be randomly assigned with a 1:1 ratio to either no antibiotic treatment or anti-pseudomonal antibiotic treatment with i.v. beta-lactam and oral ciprofloxacin for 14 days. The primary outcome, analyzed with two co-primary endpoints, is (i) time to prednisolone and/or antibiotic requiring exacerbation or death, in the primary or secondary health sector, within days 20-365 from study allocation and (ii) days alive and without exacerbation within days 20-365 from the study allocation. Discussion: This trial will determine whether targeted antibiotics can benefit future patients with chronic, non-CF pulmonary disease and P. aeruginosa infection in terms of reduced morbidity and mortality, thus optimizing therapeutic approaches in this large group of chronic patients. Trial registration: ClinicalTrials.gov NCT03262142. Registered on August 25, 2017. In the experiment, the researchers used many compounds, for example, 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid (cas: 85721-33-1Synthetic Route of C17H18FN3O3).
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid (cas: 85721-33-1) belongs to piperazine derivatives. Piperazine is a fairly basic compound and is an amine solvent. Piperazine is formed as a co-product in the ammoniation of 1,2-dichloroethane or ethanolamine. These are the only routes to the chemical used commercially.Synthetic Route of C17H18FN3O3
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics